JANSSEN PHARMACEUTICAL COMPANIES OF JOHNSON & JOHNSON
SELECTED PHARMACEUTICALS IN LATE STAGE U.S. AND E.U. DEVELOPMENT OR REGISTRATION as of 7/14/15

Therapeutic Area	Product Name	Indication Sought	U.S. Development Stage	E.U. Development Stage
Cardiovascular and Metabolism	XARELTO® (rivaroxaban)	Reduce the risk of major adverse cardiac events (MACE) in patients with Chronic Heart Failure and significant Coronary Artery Disease	Phase III	
		Prevention of Symptomatic VTE and VTE-related death in high-risk, medically ill pts	Phase III	
		Secondary prevention of stroke in patients who have experienced Embolic Stroke of undetermined source (ESUS)	Phase III	
		Reduce the risk of MACE in patients with coronary or Peripheral Artery Disease	Phase III	
	INVOKANA® (canagliflozin)	Fixed Dose Combination with Metformin, Extended Release (XR) (2)	Phase III	
		Initial Therapy Fixed Dose Combination with Metformin, Immediate Release (IR) (2)	Phase III	
		Diabetic nephropathy	Phase III	Phase III
Immunology	guselkumab	Moderate to Severe Plaque Psoriasis	Phase III	Phase III
	SIMPONI® (golimumab)	Active non-radiographic Axial Spondylarthritis		Approved 6/15
	SIMPONI® ARIA™ (golimumab)	Ankylosing spondylitis	Phase III	
		Psoriatic arthritis	Phase III	
		Juvenile Idiopathic Arthritis (JIA)	Phase III	
	sirukumab	Rheumatoid Arthritis (2)	Phase III	Phase III
	STELARA® (ustekinumab)	Crohn's Disease	Phase III	Phase III
		Moderate to Severe Plaque Psoriasis in pediatric patients		Approved 6/15
Infectious Diseases and Vaccines	PREZISTA® STR (darunavir/cobicistat/emtricitabine/tenofovir alafenamide)	Single tablet regimen for HIV in treatment naïve patients and treatment experienced patients (2)	Phase III	Phase III
	EDURANT® (rilpiravine)	HIV in pediatric patients	Filed 2/15	Filed 3/15
	EDURANT® STR (rilpirivine/emtricitabine/tenofovir alafenamide)	Single tablet regimen for HIV in naïve and treatment experienced patients (2)	Filed 7/15	Phase III
	EDURANT® STR (rilpirivine and dolutegravir)	Single tablet regimen for HIV in treatment experienced patients (2)	Phase III	Phase III
Neuroscience	INVEGA TRINZA ™ (paliperidone palmitate IM long acting injectable)	Schizophrenia - 3 month injectable (2)	Approved 5/15	Phase III
Oncology	daratumumab	Double refractory multiple myeloma (MMY2002) (2)	Filed 7/15**	Phase II
		Relapsed/refractory multiple myeloma in combination with lenalidomide/dexamethasone (MMY3003) (2)	Phase lll	Phase lll
		Relapsed/refractory multiple myeloma in combination with bortezomib/dexamethasone (MMY3004) (2)	Phase III	Phase III
		Frontline multiple myeloma transplant ineligible patients in combination with bortezomib, melphalan, and prednisone (MMY 3007) (2)	Phase III	Phase III
		Frontline multiple myeloma transplant ineligible patients in combination with lenalidomide and low dose dexamethasone (MMY 3008) (2)	Phase III	Phase III
	IMBRUVICA® (ibrutinib)	Relapsed/refractory patients with Chronic Lymphocytic Leukemia (in combination with Bendamustine and Rituximab) (randomized study CLL-3001) (2)	Phase III	Phase III
		Treatment naïve patients with Chronic Lymphocytic Leukemia (single agent) (randomized study PCYC-1115) (2)	Phase III	Phase III
		Relapsed/refractory with Mantle Cell Lymphoma (single agent) (randomized study MCL-3001) (2)	Phase III	Phase III
		Treatment naïve patients with Mantle Cell Lymphoma in combination with Bendamustine and Rituximab (randomized study MCL-3002) (2)	Phase III	Phase III
		Relapsed/refractory patients with Indolant Non-Hodgkins Lymphoma in combination with Bendamustine and Rituximab or R-CHOP; (randomized study FLR-3001) (2)	Phase III	Phase III
		Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma in combination with R-CHOP (randomized study DBL3001) (2)	Phase III	Phase III
		Previously Treated Adults with Waldenstrom's Macroglobulinemia with Rituximab (PCYC-1127) (2)	Phase III	Phase III
		Previously Treated Adults with Waldenstrom's Macroglobulinemia (PCYC-1118) (2)	Approved 1/15	Approved 7/15
		Frontline Chronic Lymphocytic Leukemia (Young and Fit) (in combination with Rituximab) (ECOG 1912) (2)	Phase III	
		Frontline Chronic Lymphocitic Leukemia in combination with obinutuzumab (PCYC-1130) (2)	Phase III	Phase III
	JNJ927/ARN-509	Prostate cancer non-metastatic castration-resistant	Phase III	Phase III
	JNJ927/ARN-509 / ZYTIGA® (abiraterone acetate)	Prostate Cancer metastatic castration resistant chemotherapy naïve	Phase III	Phase III
	YONDELIS® (trabectedin)	Soft Tissue Sarcoma (2)	Filed 11/14	
		Relapsed Ovarian Cancer (2)	Phase III	
	ZYTIGA® (abiraterone acetate)	Prostate Cancer Newly Diagnosed Hormone Naïve Metastatic		Phase III

*** This information is accurate as of the date hereof to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information.** ** Completion of rolling submission

(2) INVOKANA licensed from Mitsubishi Tanabe Pharma Corporation; PREZISTA STR and EDURANT STR (R/F/TAF) developed in collaboration with Gilead Sciences; EDURANT STR developed in collaboration with ViiV Healthcare; YONDELIS developed in collaboration with PharmaMar S.A.; XARELTO co-developed with Bayer HealthCare; INVEGA SUSTENNA developed in collaboration with Alkermes, Inc.; Daratumumab licensed from Genmab A/S; IMBRUVICA devloped in collaboration with Pharmacyclics, LLC; Sirukumab developed in collaboration with GlaxoSmithKline

Janssen Pharmaceutical Companies of Johnson & Johnson
Selected NME Pharmaceutical Pipeline - Recent Approvals/Potential Filings*
Selective Highlights as of July 14, 2015

APPROVED 2014/2015

Infectious Diseases & Vaccines

OLYSIO® (EU)
(simeprevir)
Chronic Hepatitis C virus

SIRTURO® (EU)
(bedaquiline)
Multi-drug resistant tuberculosis

Oncology

IMBRUVICA®
(ibrutinib)
Previously treated MCL
Previously treated CLL
Previously treated CLL with del 17p

SYLVANT®
(siltuximab)
Multicentric Castleman's disease

IN REGISTRATION

Oncology

YONDELIS® (US)
2nd Line soft tissue sarcoma

Daratumumab (US)
Double Refractory multiple myeloma

PLANNED FILINGS 2015-2019*

Immunology

Sirukumab
Rheumatoid arthritis

Guselkumab
Psoriasis

Neuroscience

Esketamine
Treatment resistant depression

Fulranumab
Osteoarthritis pain

JNJ-922 (Orexin-2 antagonist)
Primary insomnia

Oncology

JNJ-927 (ARN-509)
pre-metastatic prostate cancer

Daratumumab (EU)
Double Refractory multiple myeloma

JNJ-493 (FGFRI kinase inhibitor)
Urothelial cancer

Imetelstat
Relapsed/refractory myelofibrosis

Infectious Diseases & Vaccines

Monovalent Ebola
Vaccine regimen

JNJ-872
Influenza A

AL-8176
RSV infection

AL-335
HCV

* Filings/approvals assumed to be in the US and EU unless otherwise noted. This information is accurate as of the date hereof to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information. OLYSIO developed in collaboration with Medivir AB; Sirukumab developed in collaboration with GlaxoSmithKline; IMBRUVICA developed in collaboration with Pharmacyclics, LLC.; Daratumumab licensed from Genmab A/S; YONDELIS developed in collaboration with Pharma Mar S.A.; Fulranumab licensed from Amgen; Orexin – 2 antagonist codeveloped with Minerva Neurosciences; Imetelstat licensed from Geron; JNJ-872 licensed from Vertex Pharmaceuticals, Inc.